You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Field Portable Mass Spectrometry for Small Molecule Drugs in Clinical Samples

    SBC: SPECTRAL ENERGIES LLC            Topic: CBD181006

    We propose a novel two-dimensional mass spectrometry (2D-MS) technique based on ion trap arrays to identify illicit and designer drugs. This approach will give an unprecedented multiplex advantage for miniature mass spectrometry, allowing novice field technicians to rapidly identify drugs affecting the central nervous system based on both the m/z ratio and fragmentation pattern of an ion. Towards ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Extended Release of Pyridostigmine Bromide for Effectively Combating Nerve Agent Exposure

    SBC: Innosense Llc            Topic: CBD181004

    Chemical warfare agents such as the lethal nerve agent soman are a major source of risk to military personnel. Currently, pyridostigmine bromide (PB) is the only FDA-approved pretreatment to counteract the effects of soman. The rationale behind PB administration is that it acts as a “temporary” inhibitor of AChE. This precludes nerve agents from irreversible inactivation of AChE, thereby mitig ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  3. Sequential Phase II Proposal for Smartphone Application for Mask Sizing and Projecting Quantitative Fit

    SBC: Physical Optics Corporation            Topic: CBD181006

    To address the Chemical and Biological Defense (CBD) need for a field-portable mass spectrometer for small molecule drugs in clinical samples, Physical Optics Corporation (POC) proposes to develop a new FiEldable DRug Mass Analysis (FERMA) system based on a combination of portable mass spectrometry technology with laser desorption/ionization for use with aqueous clinical samples. The FERMA system ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  4. Dual Formulation of Atropine/Scopolamine with Enhanced Stability

    SBC: CMC PHARMACEUTICALS INC            Topic: CBD181005

    CMC Pharmaceuticals, Inc. (Cleveland, OH) is proposing developing a stable, combination product of two small molecule drug candidates as a counter measure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacological profiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    SBC: EVRYS BIO LLC            Topic: CBD18A002

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORP            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. HawkEye MicroLens Hyperspectral Imager for Standoff Chemical Detection

    SBC: SA Photonics, Inc.            Topic: CBD171002

    SA Photonics is please to submit the proposal for the HawkEye compact LWIR hyperspectral imaging system. HawkEye leverages SA Photonicsprevious visible, SWIR, and LWIR programs to result in a compact, hand held, battery operated hyperspectral imager in a low cost designapproach. Furthermore, HawkEye will leverages SA Photonics expertise in warfighter body worn equipment and ground troop personaleq ...

    SBIR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government